Ankylosing spondylitis
Conference Coverage
FDA’s Woodcock: Give biosimilars a chance
BOSTON – Biosimilar drugs are not identical twins of original biologic agents, but there are very strong family ties, and the newcomer is expected...
Conference Coverage
Biosimilars face barriers to broader acceptance
BOSTON – For rheumatologists, the primary selling points of biosimilar agents are their presumed efficacy and safety, and their promised cost...
From the Journals
Intravitreal sirolimus proves effective in reducing noninfectious uveitis inflammation
Intravitreal sirolimus 440 mcg or 880 mcg administered on days 1, 60, and 120, was shown to significantly improve ocular inflammation with...
From the Journals
TNF inhibitors’ effect on ankylosing spondylitis progression may be greatest after 6 years
The benefits of treatment with TNF-alpha inhibitors in reducing spinal radiographic progression in ankylosing spondylitis became most evident 6-8...
From the Journals
Most children with JIA get different diagnosis as adults
Two-thirds of children diagnosed with juvenile idiopathic arthritis are classified later as having a different form of arthritis as adults, with...
News
Biosimilar version of etanercept gains FDA approval
A biosimilar of etanercept received clearance for marketing from the FDA for all of the inflammatory disease indications held by the reference...
Conference Coverage
Ankylosing spondylitis patients develop multiple comorbidities after diagnosis
Key clinical point: In the 3 years after initial ankylosing spondylitis diagnosis, the incidence of several comorbidities rises significantly...
Conference Coverage
MRI now anchors spondyloarthritis diagnosis
Conference Coverage
Revised axial spondyloarthritis classification criteria remain elusive
Conference Coverage
Concurrent fibromyalgia intensifies ankylosing spondylitis symptoms
Key clinical point: Nearly half of patients with ankylosing spondylitis had concurrent fibromyalgia at one U.S.